Pricing
PBM Deal Heralds Escalating Price War with Drugmakers
This month's announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager Catamaran puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Mike Griffith ...Read more
Biosimilars
Biosimilars Ramp-Up: Five Themes for the Future
Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma. Casey McDonald reports ...Read more
Embedding patient centricity
Understanding the role of real-world evidence in global market access strategies
Live webinar: Tuesday, April 28, 2015 - 11.00 EDT, 17.00 CEST
Join Dr Louise Parmenter, and Dr Stella Blackburn from Qunitiles and Dr Seleen Ong from Pfizer as they discuss the importance of embedding patient centricity into the development of real-world evidence in global market access strategies.
Register for free: www.pharmexec.com/pe/quintiles-rwe
Patent Strategy Implications in the Biosimilars Space
Colleen Tracy James and Neil DuChez ask, Is biosimilar litigation the new frontier as predicted or an area pursued less vigorously as under the Hatch-Waxman Act because of cost and manufacturing obstacles? ...Read more
Legal
Pharma Distribution Deals Raise Concerns
With large pharmaceutical benefit managers such as Express Scripts beginning to use their heft to strike exclusive drug deals in order to lower the cost of healthcare, Matthew Cantor asks, does patient choice matter to antitrust enforcers?
...Read more
Leadership
Final Deadline for Nomination: Pharm Exec's 2015 Emerging Pharma Leaders
Pharm Exec is looking for the fresh faces of pharma leadership, and we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague — or yourself. The deadline for this year’s entries is Friday.
...Read more
|
